Adsorption behavior of a surfactant and a monoclonal antibody to sterilizing-grade filters

Journal of Pharmaceutical Sciences

Volumn 99, Issue 6, 2010, Pages 2620-2627

  Mahler, Hanns Christian ^a,c   Huber, Franziska ^a   Kishore, Ravuri S K ^b,c   Reindl, Jürgen ^a   Rückert, Peter ^a   Müller, Robert ^a,c  

^a MERCK KGAA   (Germany)

^b UNIVERSITY OF GENEVA   (Switzerland)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Adsorption; Biotechnology; Filtration; Protein formulation; Proteins; Surfactants; polysorbate; Tween

Indexed keywords

CELLULOSE ACETATE; MONOCLONAL ANTIBODY; NYLON; POLYETHERSULFONE; POLYMER; POLYSORBATE 80; POLYVINYLDIFLUORIDE; UNCLASSIFIED DRUG;

ADSORPTION; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; FILTRATION; MEMBRANE FILTER; SCALE UP;

EID: 77951565346     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22045     Document Type: Article

References (36)

1. Leader B, Baca QJ, Golan DE. 2008. Protein therapeutics: A summary and pharmacological classification. Nat Rev Drug Discov 7:21-39.
2. Carpenter JF, Kendrick BS, Chang BS, Manning MC, Randolph TW. 1999. Inhibition of stress-induced aggregation of protein therapeutics. Methods Enzymol 309:236-255. (Pubitemid 29446453)
3. Cleland JL, Powell MF, Shire SJ. 1993. The development of stable protein formulations-A close look at protein aggregation, deamidation, and oxidation. Crit Rev Ther Drug 10:307-377.
4. Wang W. 2005. Protein aggregation and its inhibition in biopharmaceutics. Int J Pharm 289:1-30. (Pubitemid 40093537)
5. Nema S, Washkuhn RJ, Brendel RJ. 1997. Excipients and their use in injectable products. PDA J Pharm Sci Technol 51:166-171. (Pubitemid 28123757)
6. Jones LS, Bam NB, Randolph TW. 1997. Surfactant-stabilized protein formulations: A review of protein-surfactant interactions and novel analytical methodologies. In: Shahrokh Z, Cleland JL, Shire SJ, editors. Therapeutic proteins and protein formulation and delivery. Washington, DC: American Chemical Society Symposium Series 675. pp 206-222.
7. Randolph TW, Jones LS. 2002. Surfactant-protein interactions. In: Carpenter JF, Manning MC, editors. Rational design of stable protein formulations-Theory and practice. New York: Kluwer Academic/Plenum Publishers. pp 159-175.
8. Chang BS, Kendrick BS, Carpenter JF. 1996. Surface-induced denaturation of proteins during freezing and its inhibition by surfactants. J Pharm Sci 85:1325-1330.
9. Kreilgaard L, Jones LS, Randolph TW, Frokjaer S, Flink JM, Manning MC, Carpenter JF. 1998. Effect of Tween 20 on freeze-thawing- and agitation-induced aggregation of recombinant human factor XIII. J Pharm Sci 87:1597-1603. (Pubitemid 28559648)
10. Miller R, Fainerman VB, Makievski AV, Kragel J, Grigoriev DO, Kazakov VN, Sinyachenko OV. 2000. Dynamics of protein and mixed protein/surfactant adsorption layers at the water/ fluid interface. Adv Colloid Interface 86:39-82. (Pubitemid 30582777)
11. Miller R, Fainerman VB, Makievski AV, Kragel J, Wustneck R. 2000. Adsorption characteristics of mixed monolayers of a globular protein and a non-ionic surfactant. Colloid Surf A 161:151-157.
12. Dickinson E. 1998. Proteins at interfaces and in emulsions - Stability, rheology and interactions. J Chem Soc Faraday T 94:1657-1669. (Pubitemid 128759981)
13. Chi EY, Krishnan S, Randolph TW, Carpenter JF. 2003. Physical stability of proteins in aqueous solution: Mechanism and driving forces in nonnative protein aggregation. Pharm Res 20:1325-1336. (Pubitemid 37164039)
14. Katakam M, Bell LN, Banga AK. 1995. Effect of surfactants on the physical stability of recombinant human growth hormone. J Pharm Sci 84:713-716.
15. Mahler HC, Muller R, Friess W, Delille A, Matheus S. 2005. Induction and analysis of aggregates in a liquid IgG1-antibody formulation. Eur J Pharm Biopharm 59:407-417. (Pubitemid 40342515)
16. Treuheit MJ, Kosky AA, Brems DN. 2002. Inverse relationship of protein concentration and aggregation. Pharm Res 19:511-516.
17. Charman SA, Mason KL, Charman WN. 1993. Techniques for assessing the effects of pharmaceutical excipients on the aggregation of porcine growth hormone. Pharm Res 10:954-962.
18. Bam NB, Cleland JL, Yang J, Manning MC, Carpenter JF, Kelley RF, Randolph TW. 1998. Tween protects recombinant human growth hormone against agitation-induced damage via hydrophobic interactions. J Pharm Sci 87:1554-1559. (Pubitemid 28559641)
19. Chou DK, Krishnamurthy R, Randolph TW, Carpenter JF, Manning MC. 2005. Effects of Tween 20 and Tween 80 on the stability of Albutropin during agitation. J Pharm Sci 94:1368-1381. (Pubitemid 40904199)
20. Kerwin BA, Heller MC, Levin SH, Randolph TW. 1998. Effects of Tween 80 and sucrose on acute short-term stability and long-term storage at -20 degrees C of a recombinant hemoglobin. J Pharm Sci 87:1062-1068.
21. Vidanovic D, Milic Askrabic J, Stankovic M, Poprzen V. 2003. Effects of nonionic surfactants on the physical stability of immunoglobulin G in aqueous solution during mechanical agitation. Pharmazie 58:399-404. (Pubitemid 36733849)
22. Anchordoquy TJ, Izutsu KI, Randolph TW, Carpenter JF. 2001. Maintenance of quaternary structure in the frozen state stabilizes lactate dehydrogenase during freeze-drying. Arch Biochem Biophys 390:35-41.
23. Heller MC, Carpenter JF, Randolph TW. 1999. Protein formulation and lyophilization cycle design: Prevention of damage due to freeze-concentration induced phase separation. Biotechnol Bioeng 63:166-174.
24. Hillgren A, Lindgren J, Alden M. 2002. Protection mechanism of Tween 80 during freeze-thawing of a model protein, LDH. Int J Pharm 237:57-69. (Pubitemid 34310479)
25. Carpenter JF, Arakawa T, Crowe JH. 1992. Interactions of stabilizing additives with proteins during freeze-thawing and freeze-drying. Dev Biol Stand 74:225-238; discussion 238-1229
26. Jones LS, Randolph TW, Kohnert U, Papadimitriou A, Winter G, Hagmann ML, Manning MC, Carpenter JF. 2001. The effects of Tween 20 and sucrose on the stability of anti-L-selectin during lyophilization and reconstitution. J Pharm Sci 90:1466-1477. (Pubitemid 32979742)
27. Dassinger M, Grohmann I, Jung B, Kuhlmann A, Löwe M, Pfleger A, Schiel N, Schwinn A, Selz C, Sieprath S, Sy K. 2009. Rote Liste - Fachinformation für Deutschland. ed., Frankfurt/ Main, Germany: Rote Liste Dervice GmbH. p 2000.
28. PDR. 2007. Physician's Desk Reference. 61 ed. Montvale: Thomson PDR. p 3536.
29. Shah D, Johnston TP, Heitz S, Mitra AK. 1998. The effects of various excipients on the unfolding of basic fibroblast growth factor. PDA J Pharm Sci Technol 52:209-214. (Pubitemid 28548898)
30. Powell MF, Nguyen T, Baloian L. 1998. Compendium of excipients for parenteral formulations. PDA J Pharm Sci Technol 52:238-311.
31. Paria S, Khilar KC. 2004. A review on experimental studies of surfactant adsorption at the hydrophilic solid-water interface. Adv Colloid Interface 110:75-95.
32. Mahler HC, Printz M, Kopf R, Schuller R, Muller R. 2008. Behaviour of polysorbate 20 during dialysis, concentration and filtration using membrane separation techniques. J Pharm Sci 97:764-774. (Pubitemid 351293879)
33. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, Fujimoto EK, Goeke NM, Olson BJ, Klenk DC. 1985. Measurement of protein using bicinchoninic acid. Anal Biochem 150:76-85.
34. Lämmli UK. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685.
35. Brose DJ, Waibel P. 1996. Adsorption of proteins to commercial microfiltration capsules. Pharm Technol 20:48-452. (Pubitemid 26359535)
36. Zhou JX, Qiu JS, Jiang G, Zhou C, Bingham N, Yeung H, Dransart B, Wadhwa MV, Tressel T. 2008. Non-specific binding and saturation of polysorbate-20 with aseptic filter membranes for drug substance and drug product during mAb production. J Membr Sci 325:735-741.